TY - JOUR
T1 - Improvements and Limitations of Humanized Mouse Models for HIV Research
T2 - NIH/NIAID "meet the Experts" 2015 Workshop Summary
AU - Akkina, Ramesh
AU - Allam, Atef
AU - Balazs, Alejandro B.
AU - Blankson, Joel N.
AU - Burnett, John C.
AU - Casares, Sofia
AU - Garcia, J. Victor
AU - Hasenkrug, Kim J.
AU - Kashanchi, Fatah
AU - Kitchen, Scott G.
AU - Klein, Florian
AU - Kumar, Priti
AU - Luster, Andrew D.
AU - Poluektova, Larisa Y.
AU - Rao, Mangala
AU - Sanders-Beer, Brigitte E.
AU - Shultz, Leonard D.
AU - Zack, Jerome A.
N1 - Publisher Copyright:
© Copyright 2016, Mary Ann Liebert, Inc. 2016.
PY - 2016/2
Y1 - 2016/2
N2 - The number of humanized mouse models for the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and other infectious diseases has expanded rapidly over the past 8 years. Highly immunodeficient mouse strains, such as NOD/SCID/gamma chainnull (NSG, NOG), support better human hematopoietic cell engraftment. Another improvement is the derivation of highly immunodeficient mice, transgenic with human leukocyte antigens (HLAs) and cytokines that supported development of HLA-restricted human T cells and heightened human myeloid cell engraftment. Humanized mice are also used to study the HIV reservoir using new imaging techniques. Despite these advances, there are still limitations in HIV immune responses and deficits in lymphoid structures in these models in addition to xenogeneic graft-versus-host responses. To understand and disseminate the improvements and limitations of humanized mouse models to the scientific community, the NIH sponsored and convened a meeting on April 15, 2015 to discuss the state of knowledge concerning these questions and best practices for selecting a humanized mouse model for a particular scientific investigation. This report summarizes the findings of the NIH meeting.
AB - The number of humanized mouse models for the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and other infectious diseases has expanded rapidly over the past 8 years. Highly immunodeficient mouse strains, such as NOD/SCID/gamma chainnull (NSG, NOG), support better human hematopoietic cell engraftment. Another improvement is the derivation of highly immunodeficient mice, transgenic with human leukocyte antigens (HLAs) and cytokines that supported development of HLA-restricted human T cells and heightened human myeloid cell engraftment. Humanized mice are also used to study the HIV reservoir using new imaging techniques. Despite these advances, there are still limitations in HIV immune responses and deficits in lymphoid structures in these models in addition to xenogeneic graft-versus-host responses. To understand and disseminate the improvements and limitations of humanized mouse models to the scientific community, the NIH sponsored and convened a meeting on April 15, 2015 to discuss the state of knowledge concerning these questions and best practices for selecting a humanized mouse model for a particular scientific investigation. This report summarizes the findings of the NIH meeting.
UR - http://www.scopus.com/inward/record.url?scp=84958978795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958978795&partnerID=8YFLogxK
U2 - 10.1089/aid.2015.0258
DO - 10.1089/aid.2015.0258
M3 - Article
C2 - 26670361
AN - SCOPUS:84958978795
SN - 0889-2229
VL - 32
SP - 109
EP - 119
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 2
ER -